Axsome Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2013
Net Income	-239.24	-187.13	-130.4	-102.9	-68.35	Upgrade
Depreciation & Amortization	8.28	5.56	1.16	0.08	0.04	Upgrade
Share-Based Compensation	62.62	37.73	20.8	14.76	6.12	Upgrade
Other Operating Activities	23.25	27.33	0.22	9.61	15.82	Upgrade
Operating Cash Flow	-145.08	-116.51	-108.23	-78.46	-46.38	Upgrade
Capital Expenditures	-0.58	-0.7	-0.31	-0.05	-0.02	Upgrade
Acquisitions	0	-53	0	0	0	Upgrade
Investing Cash Flow	-0.58	-53.7	-0.31	-0.05	-0.02	Upgrade
Share Issuance / Repurchase	271.17	250.01	11.84	15.18	239.63	Upgrade
Debt Issued / Paid	83.56	44.51	-0.31	27.24	12.76	Upgrade
Other Financing Activities	-23.71	-9.95	-0.4	-	-	Upgrade
Financing Cash Flow	331.01	284.58	11.13	42.41	252.39	Upgrade
Net Cash Flow	185.35	114.37	-97.4	-36.09	206	Upgrade
Free Cash Flow	-145.66	-117.21	-108.53	-78.5	-46.39	Upgrade
Free Cash Flow Margin	-53.83%	-234.25%	-	-	-	Upgrade
Free Cash Flow Per Share	-3.21	-2.88	-2.88	-2.11	-1.36	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).